At the 11th Congress European Academy of Neurology, which was held in Helsinki June 21 to June 24, researchers presented new data on using CAR T cells in autoimmune neurological conditions.
Transthera Sciences Inc. debuted on the Hong Kong stock exchange June 23 with a HK$200.95 million (US$25.6 million) IPO, becoming the latest in a string of mainland Chinese biopharmaceutical firms to turn to the Hong Kong market for capital.
Harbour Biomed is out-licensing its B-cell maturation antigen and CD3 bispecific T-cell engager HBM-7020 for autoimmune diseases to Otsuka Pharmaceutical Co. Ltd. in a deal worth up to $670 million.
A global consortium led by Adaptvac ApS aims to design and test a new vaccine that could offer broad protection against several filoviruses, including Zaire ebolavirus, Sudan ebolavirus and Marburg virus.
Harbour Biomed Ltd. has established a global strategic collaboration with Otsuka Pharmaceutical Co. Ltd. to advance BCMAxCD3 bispecific T-cell engagers for the treatment of autoimmune diseases.
Chimeric antigen receptor (CAR) T-cell therapy has been a game changer in the treatment of B-cell malignancies, although their manufacturing process is complex and needs lymphodepletion, thus limiting their use. Researchers from Capstan Therapeutics Inc. have recently published data regarding an in vivo engineering approach to generate CAR T cells using targeted lipid nanoparticles (LNPs) for mRNA delivery to specific T-cell populations for the treatment of cancer and B-cell-mediated autoimmune diseases.
Shanghai Yao Yuan Biotechnology Ltd., also known as Drug Farm, is advancing a portfolio of immune-modulating therapies for various indications including hepatitis B virus, hepatocellular cancer and a relatively new rare genetic disease called ROSAH, an acronym for retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis, and headache.
Researchers from Purdue University and the U.S. Centers for Disease Control and Prevention have recently developed a novel influenza vaccine candidate that uses a bovine adenoviral (BAd) vector to deliver nucleoprotein (NP) antigens from both influenza A and B viruses, along with an autophagy-inducing peptide (C5) to enhance cellular immune responses, particularly T-cell responses.
Chinese researchers are preparing the details for the publication of another scientific milestone, the creation of a chimera with a human heart and a kidney developed from human stem cells in pig embryos.
CSPC Pharmaceutical Group Ltd. announced June 13 that it struck a potential $5.33 billion deal with Astrazeneca plc to develop novel preclinical small-molecule candidates using CSPC’s AI-driven drug development platform.
RSS
